Deloitte Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru – 560 001
Karnataka, India

Tel: +91 80 6188 6000
Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ONESOURCE SPECIALTY PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **OneSource Specialty Pharma Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the LODR Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Sl. No.	Name of the entities
1	OneSource Specialty Pharma Limited, the Parent
2	OneSource Specialty PTE. Limited, wholly owned subsidiary
3	Strides Pharma Services Private Limited, wholly owned subsidiary
4	Biolexis Private Limited, wholly owned subsidiary
5	OneSource Specialty Pharma Inc, wholly owned subsidiary
6	OneSource Softgels PTE. Ltd., step-down subsidiary
7	Biolexis PTE. Ltd, step-down subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the LODR Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of two subsidiaries (including step-down subsidiary) included in the Statement of Unaudited Consolidated Financial Results, whose interim financial information reflect total revenues of Rs. 283.47 million for the quarter ended June 30,

Deloitte
Haskins & Sells

2026, total net loss after tax of Rs. 12.14 million for the quarter ended June 30, 2026 and other comprehensive income of Rs. 12.44 million for the quarter ended June 30, 2026 as considered in the Statement. This interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries (including step-down subsidiary) is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matter.

7. The Statement of Unaudited Consolidated Financial Results includes the financial information of four subsidiaries (including step-down subsidiaries) which have not been reviewed/audited by their auditors, whose interim financial information reflect total revenue of Rs. Nil for the quarter ended June 30, 2026, total loss after tax of Rs. 1.79 million for the quarter ended June 30, 2026 and other comprehensive income of Rs. Nil for the quarter ended June 30, 2026 as considered in the Statement.

   According to the information and explanations given to us by the Management, the above interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

Sandeep Ramesh Kukreja
Digitally signed by Sandeep Ramesh Kukreja
Date: 2026.07.24 18:11:46 +05'30'

Sandeep Kukreja
Partner
(Membership No. 220411)
(UDIN: 26220411WVTACH7913)

Place: Bengaluru
Date: July 24, 2026

OneSource Specialty Pharma Limited
Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026

Rs. in Million, except per share data

Sl No	Particulars	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Refer note 7)	(Unaudited)	(Audited)
	Income				
1	Revenue from operations	4,490.23	4,282.17	3,272.70	14,215.90
2	Other income	38.02	20.93	52.68	150.22
3	**Total income (1+2)**	**4,528.25**	**4,303.10**	**3,325.38**	**14,366.12**
4	**Expenses**				
	(a) Cost of materials consumed	422.97	876.75	462.28	2,481.53
	(b) Changes in inventories of finished goods and work-in-progress	11.33	17.55	95.57	78.94
	(c) Consumables	988.88	568.35	371.34	1,886.02
	(d) Employee benefits expense	686.80	627.42	584.38	2,422.53
	(e) Finance costs	308.09	225.13	274.78	1,221.85
	(f) Depreciation and amortisation expense	717.46	718.26	678.03	2,790.93
	(g) Other expenses	1,146.78	1,272.89	874.29	4,304.66
	Total expenses (4)	**4,282.31**	**4,306.35**	**3,340.67**	**15,186.46**
5	**Profit/(loss) before exceptional items and tax (3-4)**	**245.94**	**(3.25)**	**(15.29)**	**(820.34)**
6	Exceptional items - gain / (loss) (net) (refer note 4)	(43.00)	0.33	(28.70)	(99.27)
7	**Profit/(Loss) before tax (5+6)**	**202.94**	**(2.92)**	**(43.99)**	**(919.61)**
8	**Income tax expense**				
	Current tax	2.81	4.97	2.01	22.12
	Deferred tax	(49.84)	(53.86)	(44.14)	(203.70)
	Total tax expense	**(47.03)**	**(48.89)**	**(42.13)**	**(181.58)**
9	**Profit/(Loss) after tax (7-8)**	**249.97**	**45.97**	**(1.86)**	**(738.03)**
10	**Other Comprehensive Income**				
	Items that will not be reclassified to statement of profit and loss				
	- Remeasurements of post employment benefit obligations- gain	-	0.06	-	4.57
	- Fair Value Changes on Equity Investments (FVOCI) gain/(loss)	12.44	(11.47)	-	(71.19)
	Items that may be reclassified to statement of profit and loss				
	- Exchange differences in translating the financial statements of foreign operations	23.51	117.97	30.13	227.20
	Total other comprehensive income	**35.95**	**106.56**	**30.13**	**160.58**
11	**Total comprehensive income/(loss) for the period/year (11+12)**	**285.92**	**152.53**	**28.27**	**(577.45)**
12	**Paid-up equity share capital (of Rs. 1/- each)**	114.64	114.62	114.46	114.62
13	**Reserves (Other Equity)**				58,198.27
14	**Earnings/ (Loss) per share (of Rs. 1/- each):**	**(not annualised)**	**(not annualised)**	**(not annualised)**	**(annualised)**
	- Basic	2.18	0.40	(0.02)	(6.44)
	- Diluted	2.18	0.40	(0.02)	(6.44)

See accompanying notes to the Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026

OneSource Specialty Pharma Limited
Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026

1 In terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, ("Listing Requirements"), as amended, the Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 ("Statement") of OneSource Specialty Pharma Limited ('the Parent or 'the Company') and its subsidiaries (together referred to as 'the Group') has been reviewed by the Audit committee at their meeting held on July 23, 2026 and approved by the Board of Directors at their meeting held on July 24, 2026. The aforesaid results for the quarter ended June 30, 2026 has been reviewed by Deloitte Haskins & Sells, the statutory auditors of the Company, who have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2026.

2 The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Listing Requirements, as amended.

3 The Group's operations relate to only one reportable segment viz Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services. Accordingly, no separate disclosure of segment information is required.

4 **Exceptional items - gain / (loss) (net)**

(Rs. in million)

Particulars	Quarter ended			Year ended
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
Legal charges related to legacy litigation of subsidary [1]	(43.00)	(16.37)	(28.70)	(45.07)
Employees' one-time mutual separation settlement	-	-	-	(41.47)
Gratuity and Compensated absences impact under new Labour Codes[2]	-	16.70	-	(12.73)
Total	**(43.00)**	**0.33**	**(28.70)**	**(99.27)**

[1] Expenses relate to legal fees and other associated costs arising from the Prestige litigation regarding the Sputnik vaccine (refer note 6).

[2]The Company recognised a provision of Rs. 29.43 million during quarter ended December 31, 2025 towards gratuity and compensated absences based on the estimated impact of the new Labour Codes. Following the finalisation of the revised pay structure and based on an updated actuarial valuation, the Company has reversed the excess provision amounting to Rs. 16.70 million in the quarter ended March 31, 2026.

5 **Information on Standalone Financial Results**

(Rs. in million)

Particulars	Quarter ended			Year ended
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
Total Income	4,502.58	4,210.55	3,262.67	14,203.89
Profit/(loss) before tax	512.25	214.79	248.15	212.10
Profit/(loss) after tax	512.25	214.79	248.15	212.10

6 **Claims not acknowledged as debts by the Group**

Biolexis Pte Limited, ('Biolexis') subsidiary of the Company has received a claim from Prestige Biopharma Limited ('Prestige'/ 'manufacturing partner') of USD 136.32 million (Rs. 12,904.05 million) during the year ended March 31, 2023 and additional unsubstantiated claims during the period, including towards reimbursement of expenditure claiming that it suffered loss and damage due to the Contract Manufacturing Agreement to manufacture Sputnik Light Vaccine being terminated by Biolexis.

Further Biolexis denies liability, citing Prestige’s lack of readiness and approval of the manufacturing plant and lack of raw material supply readiness. Biolexis has already taken legal recourse through its external legal counsel to refute all the claims as false, baseless, and misconceived and has sought a 100% refund of the Capacity fee of USD 13.62 million (Rs.1,289.27 million) which was paid to Prestige guaranteeing the prompt refund of the Capacity fee paid to Prestige in case no manufacturing occurs within the agreed timelines.

Currently, this matter is pending before Singapore International Arbitration Centre (SIAC). The Group firmly believes that all claim from Prestige has no legal merit and that all claims are frivolous.

OneSource Specialty Pharma Limited
Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026

7 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect to financial year ended March 31, 2026 and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to limited review.

8 Figures for the previous periods, wherever necessary have been regrouped/reclassified to confirm to the current period's presentation.

For and on behalf of Board of Directors of OneSource Specialty Pharma Limited

Neeraj Sharma
Digitally signed by Neeraj Sharma
Date: 2026.07.24 17:54:59 +05'30'

Neeraj Sharma
Managing Director
DIN : 09402652

Place : Bengaluru
Date : July 24, 2026